• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

构建群体药代动力学-药效学模型。I. 协变量效应模型。

Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

作者信息

Mandema J W, Verotta D, Sheiner L B

机构信息

Department of Pharmacy, School of Pharmacy, University of California, San Francisco 94143.

出版信息

J Pharmacokinet Biopharm. 1992 Oct;20(5):511-28. doi: 10.1007/BF01061469.

DOI:10.1007/BF01061469
PMID:1287200
Abstract

One major task in clinical pharmacology is to determine the pharmacokinetic-pharmacodynamic (PK-PD) parameters of a drug in a patient population. NONMEM is a program commonly used to build population PK-PD models, that is, models that characterize the relationship between a patient's PK-PD parameters and other patient specific covariates such as the patient's (patho) physiological condition, concomitant drug therapy, etc. This paper extends a previously described approach to efficiently find the relationships between the PK-PD parameters and covariates. In a first step, individual estimates of the PK-PD parameters are obtained as empirical Bayes estimates, based on a prior NONMEN fit using no covariates. In a second step, the individual PK-PD parameter estimates are regressed on the covariates using a generalized additive model. In a third and final step, NONMEM is used to optimize and finalize the population model. Four real-data examples are used to demonstrate the effectiveness of the approach. The examples show that the generalized additive model for the individual parameter estimates is a good initial guess for the NONMEM population model. In all four examples, the approach successfully selects the most important covariates and their functional representation. The great advantage of this approach is speed. The time required to derive a population model is markedly reduced because the number of necessary NONMEM runs is reduced. Furthermore, the approach provides a nice graphical representation of the relationships between the PK-PD parameters and covariates.

摘要

临床药理学的一项主要任务是确定药物在患者群体中的药代动力学-药效学(PK-PD)参数。NONMEM是一个常用于构建群体PK-PD模型的程序,即表征患者PK-PD参数与其他患者特定协变量(如患者的(病理)生理状况、联合药物治疗等)之间关系的模型。本文扩展了一种先前描述的方法,以有效地找到PK-PD参数与协变量之间的关系。第一步,基于不使用协变量的先验NONMEN拟合,将PK-PD参数的个体估计值作为经验贝叶斯估计值获得。第二步,使用广义相加模型将个体PK-PD参数估计值对协变量进行回归。在第三步也是最后一步,使用NONMEM对群体模型进行优化和最终确定。使用四个实际数据示例来证明该方法的有效性。这些示例表明,个体参数估计值的广义相加模型是NONMEM群体模型的良好初始猜测。在所有四个示例中,该方法成功选择了最重要的协变量及其函数表示形式。这种方法的最大优点是速度快。由于减少了必要的NONMEM运行次数,推导群体模型所需的时间显著减少。此外,该方法还提供了PK-PD参数与协变量之间关系的良好图形表示。

相似文献

1
Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.构建群体药代动力学-药效学模型。I. 协变量效应模型。
J Pharmacokinet Biopharm. 1992 Oct;20(5):511-28. doi: 10.1007/BF01061469.
2
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.Xpose——一种基于S-PLUS的用于NONMEM的群体药代动力学/药效学模型构建辅助工具。
Comput Methods Programs Biomed. 1999 Jan;58(1):51-64. doi: 10.1016/s0169-2607(98)00067-4.
3
Automated covariate model building within NONMEM.NONMEM 中的自动协变量模型构建。
Pharm Res. 1998 Sep;15(9):1463-8. doi: 10.1023/a:1011970125687.
4
Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.药物计量学:用于改善临床药物开发决策的建模与模拟工具。
Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):49-58. doi: 10.1007/BF03190058.
5
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.群体药代动力学/药效学数据的同步分析与序贯分析I:最佳情况表现
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):387-404. doi: 10.1023/b:jopa.0000012998.04442.1f.
6
Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.群体药代动力学-药效学分析中逐步协变量模型构建策略的比较
AAPS PharmSci. 2002;4(4):E27. doi: 10.1208/ps040427.
7
A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.复杂药代动力学和药效学模型的群体分析方法及软件综述,并附实例
AAPS J. 2007 Mar 2;9(1):E60-83. doi: 10.1208/aapsj0901007.
8
Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.群体药代动力学/药效学分析中模型构建策略概述:2002 - 2004年文献调查
Br J Clin Pharmacol. 2007 Nov;64(5):603-12. doi: 10.1111/j.1365-2125.2007.02975.x. Epub 2007 Aug 15.
9
Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.群体药代动力学-药效学分析中时变协变量的模型
Br J Clin Pharmacol. 2004 Oct;58(4):367-77. doi: 10.1111/j.1365-2125.2004.02170.x.
10
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.参数和非参数总体方法:它们在分析临床数据集和两项蒙特卡罗模拟研究中的比较性能。
Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003.

引用本文的文献

1
Covariate Model Selection Approaches for Population Pharmacokinetics: A Systematic Review of Existing Methods, From SCM to AI.群体药代动力学的协变量模型选择方法:从结构方程模型到人工智能的现有方法系统综述
CPT Pharmacometrics Syst Pharmacol. 2025 Apr;14(4):621-639. doi: 10.1002/psp4.13306. Epub 2025 Jan 20.
2
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approaches.在群体药代动力学分析中,构建协变量模型方法对其临床相关性评价的影响:全模型、逐步协变量模型(SCM)和 SCM+方法的比较。
J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):653-670. doi: 10.1007/s10928-024-09911-0. Epub 2024 Apr 9.
3

本文引用的文献

1
Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.药代动力学的贝叶斯个体化:简单实现及与非贝叶斯方法的比较。
J Pharm Sci. 1982 Dec;71(12):1344-8. doi: 10.1002/jps.2600711209.
2
Estimating population kinetics.估计群体动力学。
Crit Rev Biomed Eng. 1982;8(3):195-222.
3
A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.一种结合贝叶斯回归和NONMEM群体分析的三步方法:应用于咪达唑仑
Covariate modeling in pharmacometrics: General points for consideration.
药物代谢动力学中的协变量建模:一般注意事项。
CPT Pharmacometrics Syst Pharmacol. 2024 May;13(5):710-728. doi: 10.1002/psp4.13115. Epub 2024 Apr 2.
4
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.特西珠单抗治疗复发/难治性多发性骨髓瘤患者的群体药代动力学和暴露-反应:MajesTEC-1 研究结果。
Target Oncol. 2023 Sep;18(5):667-684. doi: 10.1007/s11523-023-00989-z. Epub 2023 Sep 15.
5
Go beyond the limits of genetic algorithm in daily covariate selection practice.超越遗传算法在日常协变量选择实践中的局限性。
J Pharmacokinet Pharmacodyn. 2024 Apr;51(2):109-121. doi: 10.1007/s10928-023-09875-7. Epub 2023 Jul 26.
6
Pharmacodynamic-Mediated Drug Disposition (PDMDD) Model of Daratumumab Monotherapy in Patients with Multiple Myeloma.单药达雷妥尤单抗治疗多发性骨髓瘤患者的药效学介导的药物处置(PDMDD)模型。
Clin Pharmacokinet. 2023 May;62(5):761-777. doi: 10.1007/s40262-023-01232-8. Epub 2023 Apr 6.
7
Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach.利用一种基于机制的建模和模拟方法定量评估人类单次接种 COVID-19 疫苗 Ad26.COV2.S 后的抗体持久性。
Clin Pharmacol Ther. 2023 Feb;113(2):380-389. doi: 10.1002/cpt.2796. Epub 2022 Dec 9.
8
Population Pharmacokinetics and Dosing Regimen of Lithium in Chinese Patients With Bipolar Disorder.中国双相情感障碍患者锂盐的群体药代动力学及给药方案
Front Pharmacol. 2022 Jul 4;13:913935. doi: 10.3389/fphar.2022.913935. eCollection 2022.
9
Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Refractory Depression.治疗难治性抑郁症患者的氯胺酮治疗效果和不良反应的群体药代动力学和药效学。
Clin Pharmacol Ther. 2022 Sep;112(3):720-729. doi: 10.1002/cpt.2640. Epub 2022 Jun 9.
10
Quantitative Comparison of the Clinical Efficacy of 6 Classes Drugs for IgA Nephropathy: A Model-Based Meta-Analysis of Drugs for Clinical Treatments.6 类药物治疗 IgA 肾病的临床疗效的定量比较:基于模型的药物临床治疗荟萃分析。
Front Immunol. 2022 Mar 28;13:825677. doi: 10.3389/fimmu.2022.825677. eCollection 2022.
J Pharmacokinet Biopharm. 1991 Aug;19(4):377-84. doi: 10.1007/BF01061662.
4
Forecasting individual pharmacokinetics.预测个体药代动力学。
Clin Pharmacol Ther. 1979 Sep;26(3):294-305. doi: 10.1002/cpt1979263294.